Toralizumab is a monoclonal antibody that targets the human immune system, specifically designed to inhibit the activity of certain immune cells. It is primarily investigated for its potential therapeutic applications in autoimmune diseases and inflammatory conditions. As a biologic agent, Toralizumab is characterized by its large, complex structure, which is typical of monoclonal antibodies, consisting of amino acid chains that form a Y-shaped molecule. This structure allows it to bind specifically to its target, modulating immune responses. The CAS number 252662-47-8 uniquely identifies this compound in chemical databases, facilitating its study and regulation. Like other monoclonal antibodies, Toralizumab may exhibit specific pharmacokinetic properties, including a relatively long half-life, which can influence dosing regimens. Safety and efficacy profiles are typically established through clinical trials, and potential side effects may include infusion reactions or increased susceptibility to infections due to immune modulation. Overall, Toralizumab represents a significant advancement in targeted therapies for managing complex immune-related disorders.

Toralizumab

252662-47-8: Toralizumab is a monoclonal antibody that targets the human immune system, specifically designed to inhibit the activity of certain immune cells. It is primarily investigated for its potential therapeutic applications in autoimmune diseases and inflammatory conditions. As a biologic agent, Toralizumab is characterized by its large, complex structure, which is typical of monoclonal antibodies, consisting of amino acid chains that form a Y-shaped molecule. This structure allows it to bind specifically to its target, modulating immune responses. The CAS number 252662-47-8 uniquely identifies this compound in chemical databases, facilitating its study and regulation. Like other monoclonal antibodies, Toralizumab may exhibit specific pharmacokinetic properties, including a relatively long half-life, which can influence dosing regimens. Safety and efficacy profiles are typically established through clinical trials, and potential side effects may include infusion reactions or increased susceptibility to infections due to immune modulation. Overall, Toralizumab represents a significant advancement in targeted therapies for managing complex immune-related disorders.

<p>Toralizumab: humanized mAb targeting CD40L to curb T cell signaling and explore SLE treatment.</p>

CAS 252662-47-8

Toralizumab

Toralizumab

Ref: TM-T76834